Global Intragastric Balloon Market, By Type (Single, Dual, Triple intragastric balloons), Filling Material (Saline Filled, Gas Filled), End Use (Hospitals, Clinics, Ambulatory Surgical Centers, Others) – Industry Trends and Forecast to 2029.
Intragastric Balloon Market Analysis and Size
The market for intragastric balloon is expected to grow in the forecast period of 2022-2029. It is projected that rising obesity rates would fuel market expansion. The hospital segment dominated the intragastric balloon market and held the largest revenue share.
Data Bridge Market Research analyses that the intragastric balloon market which was USD 87.3 million in 2021, would rocket up to USD 201.91 million by 2029, and is expected to undergo a CAGR of 11.05% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Intragastric Balloon Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Single, Dual, Triple intragastric balloons), Filling Material (Saline Filled, Gas Filled), End Use (Hospitals, Clinics, Ambulatory Surgical Centers, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Obalon Therapeutics (U.S.), Apollo Endosurgery Inc. (U.S.), Allurion (U.S.), Spatz3 (U.S.), ReShape Lifesciences Inc. (U.S.), Hélioscopie (France), Apollo Endosurgery, Inc. (U.S.), Obalon Therapeutics, Inc. (U.S.), Endalis (France), Lexel Medical (U.S.), Districlass Medical (France), Shandong Institute of Medical Instruments (China), Phagia Technologies, Inc. (U.S.), Fengh Medical B.V. (China), Medicone Group (U.S.), BAROnova Inc. (U.K.)
The goal of the gastric balloon surgery, a new weight loss method, is to eat less at each meal and feel fuller for longer after just eating small meals. This sort of weight loss procedure, also referred to as the intragastric balloon, can aid in weight loss without requiring invasive surgery. A silicone balloon filled with saline or gas is implanted during this procedure, which helps the patient lose weight by controlling how much food they consume. Since 1985, intragastric balloons have been used often to treat obesity and promote weight loss.
Global Intragastric Balloon Market Dynamics
- Rise in minimally invasive procedures
The deflated gastric balloon is inserted into the stomach through the oesophagus. The balloon is then sealed with sterile saline solution using a syringe. Additionally, the triple intragastric balloon market is expected to rise as patients' preferences for minimally invasive procedures like as sleeve gastrectomy and gastric bypass continue to grow.
- Acceptance of weight-loss surgical intervention
Only 1.5% to 2.5% of the obese population is eligible for obesity-related operations, leading to significant obesity-related fatalities. This is due to the high prevalence of obesity and healthcare professionals' widespread acceptance of weight-loss surgical intervention, such as gastric bypass. For instance, according to statistics from the WHO, obesity and being overweight account for over 2.79 million deaths worldwide each year. The need for less intrusive treatments like an intragastric balloon is anticipated to increase as a result of this heightened death rate.
- Increase in the number of obese patients
The expansion of the segment will be accelerated by an increase in the number of obese patients around the world and better product design. The sector will expand in the next years as a result of numerous technological developments that will enhance patient outcomes and the creation of the next-generation intragastric balloon.
The intragastric balloon market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the intragastric balloon market growth.
Moreover, increasing emerging markets and new product launches will further provide beneficial opportunities for the intragastric balloon market growth during the forecast period.
On the other hand, lack of reimbursement for such procedures in most countries can potentially restrain the market demand and obstruct the market's growth rate. The market for intragastric balloons will face difficulties due to a shortage of qualified workers and inadequate healthcare infrastructure in underdeveloped nations.
This intragastric balloon market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the intragastric balloon market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Intragastric Balloon Market
The market for intragastric balloons is probably going to be significantly impacted by COVID-19. During the COVID-19 pandemic, those who have an underlying disease, such as obesity, are more at risk. Around 30.2% of all COVID-19 hospitalizations were attributable to obesity, according to statistics released by the Centers for Disease Control and Prevention in March 2021. Obesity dramatically increased during the COVID-19 epidemic. According to a December 2020 article in the European Journal of Nutrition, people's decreased exercise habits and shift in lifestyle are to blame for the global rise in obesity rates.
- In July 2020, With the debut of the Elipse Program in Hong Kong, Malaysia, and Singapore, Allurion Technologies announced its arrival into Asia and the opening of the region to non-invasive weight loss treatments.
- In January 2020, To enable the introduction of its ingestible weight loss balloon, Allurion Technologies Inc. raised almost USD 34 million. The business will use the money to expand abroad and introduce its ground-breaking weight loss method to American consumers.
Global Intragastric Balloon Market Scope
The intragastric balloon market is segmented on the basis of type, filling material and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Triple intragastric balloons
- Saline Filled
- Gas Filled
- Ambulatory Surgical Centers
Intragastric Balloon Market Regional Analysis/Insights
The intragastric balloon market is analysed and market size insights and trends are provided sby country, type, filling material and end use as referenced above.
The countries covered in the intragastric balloon market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the intragastric balloon market due to the increasing obese population and high adoption of weight loss treatments.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to a growth in unhealthy lifestyles, an increase in the prevalence of obesity, and the accessibility of affordable therapy.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Intragastric Balloon Market Share Analysis
The intragastric balloon market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to intragastric balloon market.
Some of the major players operating in the intragastric balloon market are:
- Allurion (U.S.)
- Spatz3 (U.S.)
- ReShape Lifesciences Inc. (U.S.)
- Hélioscopie (France)
- Apollo Endosurgery, Inc. (U.S.)
- Obalon Therapeutics, Inc. (U.S.)
- Endalis (France)
- Lexel Medical (U.S.)
- Districlass Medical (France)
- Shandong Institute of Medical Instruments (China)
- Phagia Technologies, Inc. (U.S.)
- Fengh Medical B.V. (China)
- Medicone Group (U.S.)
- BAROnova Inc. (U.K.)